Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Detection of B cells may predict graft-versus-host disease

Detection of B cells may predict graft-versus-host disease

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Results from Merck’s Vorinostat phase 1 trial on lymphoma

AIBioTech announces implementation of L-asparaginase activity assay for pediatric ALL

AIBioTech announces implementation of L-asparaginase activity assay for pediatric ALL

Hope against dangerous form of acute lymphoblastic leukemia

Hope against dangerous form of acute lymphoblastic leukemia

Scientists visualise molecular changes in Bax protein that force cells to die

Scientists visualise molecular changes in Bax protein that force cells to die

Notch protein responsible for activating GATA2 gene to generate hematopoietic stem cells

Notch protein responsible for activating GATA2 gene to generate hematopoietic stem cells

Bioelectric signals can identify cells that are likely to develop into tumors

Bioelectric signals can identify cells that are likely to develop into tumors

Study demonstrates new fragile genomic sites responsible for chromosomal alterations in tumors

Study demonstrates new fragile genomic sites responsible for chromosomal alterations in tumors

DelMar announces second closing of $1.5M in private placement

DelMar announces second closing of $1.5M in private placement

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

UIC to determine whether exercise can shorten recovery time for stem cell transplant patients

UIC to determine whether exercise can shorten recovery time for stem cell transplant patients

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Genentech announces positive results from GA101 plus chlorambucil Phase III study on CLL

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Feinstein Institute, Merck Serono to develop antibodies for treatment of SLE

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.